“Full Metal Jacket” Drug‐Eluting Stent Implantation
Cheol Whan Lee,Seung‐Jung Park
DOI: https://doi.org/10.1002/ccd.25695
IF: 2.3
2014-12-01
Catheterization and Cardiovascular Interventions
Abstract:Managing advanced coronary artery disease (CAD) is an increasing clinical problem with a growing number of patients with severe CAD [1]. Since the introduction of percutaneous coronary intervention, lesion length has been identified the key factor related to higher rates of restenosis. Until now, patients with very diffuse CAD tend to be treated with aggressive medical therapy because they are not usually suitable for surgical or percutaneous coronary revascularization. Balloon angioplasty or bare-metal stent implantation in these patients is associated with high risk of repeat revascularization, and rarely used in clinical practice. However, drug-eluting stents (DESs) nearly eliminate the risk of restenosis, rapidly expanding the indications for complex and challenging lesions. Full metal jacket (FMJ) DES implantation (stented length without gaps 60 mm) is not uncommon in realworld clinical practice, and increasingly used in accordance with the requirement of more complex procedures (5–10% of the total DES implantation, unpublished Korean registry data). For example, percutaneous coronary intervention of chronic total occlusion remains the most challenging area to treat in coronary interventional practice, commonly requiring FMJ stent implantation to cover full coronary artery lesions. It is well demonstrated that DESs provide better long-term clinical outcomes than bare-metal stents in various clinical settings including acute myocardial infarction, diabetes, bifurcation, chronic total occlusions, diffuse long lesions, and etc. However, there is still controversy on the efficacy and safety of FMJ approach. Limited data exist regarding the long-term clinical outcomes after FMJ DES implantation. In this issue of the Journal, Dr. Basavarajaiah et al. performed extended follow-up in 274 patients with 297 lesions in native coronary arteries, who underwent FMJ DES implantation [2]. During the median follow-up of 6.2 years, the rates of cardiac death, myocardial infarction, and target lesion revascularization were 5.8%, 6.2%, and 27.3%, respectively. The rate of definite and probable stent thrombosis was 3.6%. The most serious concern in using previous DESs was the ongoing hazard of definite stent thrombosis, with a continuing rate of 0.6%/year for very late stent thrombosis. Given the complexity of lesions treated in this study, however, the rate of definite stent thrombosis was relatively low with 0.25%/year, reassuring the skeptical physicians. Diabetes, smoking, and left ventricular ejection fraction were found to be the independent predictors of major adverse cardiac events. Likewise, smoking and final minimal stent diameter were the independent predictors of target lesion revascularization. These findings show that the long-term clinical outcomes of patients with FMJ procedure are favorable with acceptable rates of hard clinical endpoints, and the major adverse cardiac event is primarily driven by repeat revascularization. Previously, we also reported long-term clinical outcomes and predictors of major adverse cardiac events in 347 consecutive patients with 352 lesions who had been treated with FMJ DES implantation [3]. During the median follow-up of 8 years, the event-free survival rate for cardiac death, cardiac death/myocardial infarction, or cardiac death/myocardial infarction/target lesion revascularization was 90.5%, 85.8%, and 71.6%, respectively. Left ventricular dysfunction (ejection fraction 80 mm were significantly related to cardiac death/myocardial infarction. Intravascular ultrasound was used in 73% of patients. Stent underexpansion is common after the FMJ